Pope Benedict XVI encyclical letter denounces excessive zeal for assertions of intellectual property rights in knowledge

Pope Benedict XVI today issued a statement saying that “On the part of rich countries, there is excessive zeal for protecting knowledge through an unduly rigid assertion of the right to intellectual property, especially in the field of health care.” The criticism came in a section of his most recent encyclical letter dealing with social issues, and specifically focusing on international human development and systemic failures of bodies large and small to solve development problems.

Continue Reading

Uncategorized

Civil Society letter to Members of the WHO Expert Working Group on R&D Financing

Today nine NGOs sent a letter the WHO Expert Working Group on R&D Financing. The letter focuses on issues about transparency, conflicts of interest, and EWG outcomes. The whole EWG seems to be going very badly right now, in part because of the US government and much of Northern Europe is working hand and glove with the pharmaceutical industry, and partly because the Gates Foundation is protecting big pharma and seems to have an ideological attachment to strong IPR.

Continue Reading

Uncategorized

US guts transparency clause in PAHO R&D resolution

The PAHO negotiations on the R&D resolution has produced a new draft, which radically guts the provision on transparency of pharmaceutical industry economics.

The US opposed this language:

“(j) to develop, with input from Member States, a possible standard for disclosure of economic data for drug registered for sale, including disclosures of the costs of R&D, the prices of products, and the annual revenues from the sale of products.”

The US agreed to this language:

Continue Reading

Meet the chief US ACTA negotiator: Kira Alvarez, the Deputy Assistant USTR for IP Enforcement

Kira Alvarez is the Deputy Assistant USTR for Intellectual Property Enforcement, and the chief US negotiator for ACTA. According to her Linkedin bio, as late as October 2008, right before the election, she was the Time Warner Vice President for Global Public Policy, and before that, she was a lobbyist for Ely Lilly, the pharmaceutical company. Continue Reading

Uncategorized

2009: PAHO dispute over standards for transparency of economic data for pharmaceutical industry

Today the executive board of the Pan American Health Organization (PAHO) is considering a proposal to have more transparency of the economics of the pharmaceutical industry. (I have separately blogged about this on the Huffpo). Specifically, an amendment offered to a PAHO EB resolution on research, proposed the following:

Continue Reading